AllStar Health Brands Inc. announced Management has signed a Distribution Agreement for the US and Canada, with MedPharma Invest (Berberex) for the Sales & Marketing of a US-FDA registered, patented Over-the-Counter Medicine, Wound Cleanser already sold in select hospitals in the US. In addition, the agreement includes AllStar marketing a line of Berberex’s unique skin repair products. AllStar expects to begin co-marketing in the US in First Quarter 2020, in Florida and other US locations and in Canada, market exclusively once regulatory approvals are in place. AllStar believes Berberex Wound Cleanser can differentiate itself in a crowded market thanks to its patented formula which confers advantages in wound care treatment for diabetic wounds, pressure sores and surgical wounds. It kills the most common, dangerous bacteria that colonize wounds, especially in hospital environments and promotes healing.